The following are the Nasdaq 100 members that are within 20% of the 52-week low:
-
Apollo Group, Inc. (APOL) at $57.10 within 3.16%
-
Cephalon, Inc. (CEPH) at $54.58 within 3.86%
-
Genzyme Corporation (GENZ) at $50.60 within 7.45%
-
Gilead Sciences, Inc. (GILD) at $42.55 within 8.08%
-
Biogen Idec Inc (BIIB) at $42.13 within 13.22%
-
Stericycle, Inc. (SRCL) at $52.37 within 18.06%
-
Amgen Inc. (AMGN) at $53.62 within 19.26%
-
Pharmaceutical Product Developm (PPDI) at $21.55 within 19.92%
The fact that all of these companies (except for APOL) are within the drug industry does not surprise me. The continued undervaluation of these companies makes them prime targets for acquisition by investors and larger drug companies. Touc.